We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Delenex Therapeutics Extends Scientific Advisory Board
News

Delenex Therapeutics Extends Scientific Advisory Board

Delenex Therapeutics Extends Scientific Advisory Board
News

Delenex Therapeutics Extends Scientific Advisory Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Delenex Therapeutics Extends Scientific Advisory Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Delenex Therapeutics AG has announced the extension of its scientific advisory board. Two world-renowned oncology specialists will bring strong clinical, scientific and drug formulation expertise to assist Delenex in developing and implementing its corporate and R&D strategy.

The new members of the advisory board are:
Roger Stupp, M.D., Professor and Chairman of the Department of Oncology at the University of Zurich, Switzerland. He also serves as the President of the European Organization for Research and Treatment of Cancer (EORTC). Prof. Stupp is known for his practice-changing novel strategies in the field of neuro-oncology, and has made significant contributions to clinical research and the launch of novel chemotherapeutics, and

Michael Weller, M.D., Professor and Chairman of the Department of Neurology, University of Zurich, Switzerland. He serves as President of the European Association of Neuro-Oncology (EANO) and as Chairman of the Brain Tumor Group of the EORTC. Prof. Weller is an internationally renowned researcher in brain tumors and has extensive experience in the diagnosis and therapy of glioblastoma and other primary brain tumors. He is involved in many clinical protocols and is instrumental in the development of novel therapies for this highly aggressive cancer.

“We are delighted and honored to have these internationally acknowledged leaders in oncology join our advisory board,” said Thomas Hecht, Delenex’ Executive Chairman. “Their expertise will be key in advancing our therapeutic programs.”

Advertisement